416 Chemotherapy

Question 1

Chemotherapy agents

Answer 1

Antimetabolites 
Microtubule targeting agents 
Topoisomerase active agents 
Alkylating agents 
Miscellaneous agents

Question 2

Antimetabolites

Answer 2

Cytarabine
Fluorouracil
Methotrexate

Question 3

Class toxicities of antimetabolites

Answer 3

Myelosuppression

Diarrhea

Question 4

Antimetabolite: Cytarabine DLT and HMT

Answer 4

DLT/HMT: cerebellar syndrome from high dose

Question 5

Antimetabolite: Fluorouracil DLT and HMT

Answer 5

DLT/HMT: stomatitis and diarrhea

Question 6

Enhances activity AND toxicity of 5FU

Answer 6

Leucovorin

Question 7

Antimetabolite: Methotrexate DLT and HMT

Answer 7

DLT: myelosuppression, mucositis, diarrhea
HMT: myelosuppression, mucositis, diarrhea, nephrotoxicity

Question 8

DDI with methotrexate

Answer 8

Bactrim
NSAID
PPI (?)

Question 9

Given with MTX 24-36hrs pose dose

Answer 9

Leucovorin

-use with MTX doses >500

Question 10

Drug used for MTX toxicity caused by renal toxicity

Answer 10

Glucarpidase

Question 11

Microtubule-targeting agents

Answer 11

Paclitaxel
Docetaxel
Vincristine

Question 12

Microtubule-targeting agents class SE

Answer 12

Peripheral neuropathy

Question 13

Microtubule: Paclitaxel DLT and HMT

Answer 13

DLT: peripheral neuropathy
HMT: complete alopecia

Question 14

Microtubule: Docetaxel DLT and HMT

Answer 14

HMT: edema

Question 15

Microtubule: Vincristine DLT and HMT

Answer 15

DLT/HMT: peripheral neuropathy

Question 16

Topoisomerase inhibitors

Answer 16

Doxorubicin

Irinotecan

Question 17

Topoisomerase: Doxorubicin DLT and HMT

Answer 17

DLT/HMT: delayed cardiotoxicity (yrs after taking the agent)
Max accumulated dose: 450-550 mg/m2

Question 18

Topoisomerase: Irinotecan DLT and HMT

Answer 18

DLT/HMT: delayed diarrhea (>12-24hrs post dose)

-loperamide 4mg at onset and 2mg q2h until resolution

Question 19

Alkylating agents

Answer 19

Cyclophosphamide

Ifosfamide

Question 20

Alkylating agents class SE

Answer 20

Sterility/infertility/teratogenic

Carcinogenic (leukemia, myelodysplastic syndrome)

Question 21

Alkylating: Cyclophosphamide DLT and HMT

Answer 21

HMT: hemorrhagic cystitis

-trt with Mesna

Question 22

Alkylating: Ifosfamide DLT and HMT

Answer 22

HMT: hemorrhagic cystitis

Question 23

Platinum: Cisplatin and Carboplatin DLT and HMT

Answer 23

HMT: nausea, vomiting

Question 24

Platinum: Oxaliplatin DLT and HMT

Answer 24

DLT/HMT: peripheral neuropathy

Question 25

Anti-angiogenesis: Thalidomide DLT and HMT

Answer 25

HMT: teratogenicity

Question 26

Corticosteroids

Answer 26

Prednisone | Dexamethasone

Question 27

SE of corticosteroids

Answer 27

Insomnia, fluid retention, nausea, increased appetite, irritability, hyperglycemia

Question 28

Immune therapies

Answer 28

PegIFN | IL-2

Question 29

PegIFN SE

Answer 29

Flu-like symptoms | Neurologic toxicities

Question 30

IL-2 SE

Answer 30

Hypotension, fluid retention, acute renal dysfunction GI hemorrhage, stomatitis Capillary leak syndrome (high dose)

Question 31

Targeted therapy agents

Answer 31

Histone deacetylase inhibitors PARP inhibitors Proteasome inhibitors

Question 32

Histone: Panobinostat DLT and HMT

Answer 32

HMT: QT prolongation

Question 33

PARP: Olparib SE

Answer 33

Anemia, nausea, increased SCr, AML/MDS

Question 34

Proteasome: Bortezomib DLT and HMT

Answer 34

DLT/HMT: peripheral neuropathy